Market-Moving News for September 25th
Portfolio Pulse from ryanfaloona@benzinga.com
Biophytis and Skyepharma have signed a partnership agreement for the production of Sarconeos, causing Biophytis' stock (BPTS) to rise by 45%. TransCode Therapeutics (RNAZ) announced positive pre-clinical Glioblastoma results with its lead therapeutic candidate, TTX-MC138, leading to a 30% increase in its stock. NIO Inc. (NIO) announced the closing of a US$1 billion convertible senior notes offering, resulting in an 8.5% decrease in its stock.
September 25, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biophytis' stock rose by 45% following the announcement of a partnership with Skyepharma for the production of Sarconeos.
The partnership with Skyepharma for the production of Sarconeos is a positive development for Biophytis, leading to increased investor confidence and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
TransCode Therapeutics' stock increased by 30% after announcing positive pre-clinical Glioblastoma results with its lead therapeutic candidate, TTX-MC138.
The positive pre-clinical Glioblastoma results with TransCode's lead therapeutic candidate, TTX-MC138, have boosted investor confidence, leading to a rise in the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
NIO Inc.'s stock decreased by 8.5% after announcing the closing of a US$1 billion convertible senior notes offering.
The closing of a US$1 billion convertible senior notes offering by NIO Inc. has led to a decrease in the stock price, possibly due to investor concerns about increased debt.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100